Time to move beyond nigrostriatal dopamine deficiency in Parkinsons disease

Annals of Neurology

Volumn 55, Issue 6, 2004, Pages 761-765

  Lang, Anthony E ^a   Obeso, José A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; UBIDECARENONE;

BRAIN DEPTH STIMULATION; DOPAMINERGIC NERVE CELL; DYSKINESIA; EDITORIAL; HUMAN; NERVE DEGENERATION; NEUROMODULATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; CORPUS STRIATUM; DOPAMINE; ELECTRIC STIMULATION; GENE THERAPY; HUMANS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TRANSPLANTATION;

EID: 2542612292     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20102     Document Type: Editorial

References (46)

1. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neutol 2003;54:403-414.
2. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
3. Arjona V, Miinguez-Castellanos A, Montoro RJ, et al. Auto-transplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 2003;53:321-328.
4. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
5. Volkmann J, Allert N, Voges J, et al. Long-term results of bilateral pallidal stimulation in advanced Parkinson's disease. Ann Neurol 2004;55:871-874.
6. During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001;12: 1589-1591.
7. Lang AE, Obeso JA. Current challenges in Parkinson's disease: restoring the nigrostriatal dopamine system will not suffice. Lancet Neurol (in press).
8. Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease-stop or go? Nat Rev Neurosci 2001;2:365-369.
9. Lindvall O. Neural transplantation: a hope for patients with Parkinson's disease. Neuroreport 1997;8:iii-x.
10. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
11. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001;50:181-187.
12. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
13. Kordower JH, Freeman TB, Chen EY, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998;13:383-393.
14. Ma YL, Feigin A, Dhawan V, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002;52:628-634.
15. Freed CR, Breeze RE, Fahn S, Eidelberg D. Preoperative response to L-DOPA is best predictor of transplant outcome. Ann Neurol 2004;55:00-00.
16. Olanow CW, Freeman T, Kordower J. Preoperative response to Levodopa is the best predictor of transplant outcome-reply. Ann Neurol 2004;55:896-897.
17. Watts RL, Stover NP, Cornfeldt ML, et al. Stereotaxic intrastriatal implantation of retinal pigment epithelial cells attached to gelatin microcarriers: a 12-month open-label trial in 6 advanced Parkinson's disease (PD) patients. Mov Disord 2002; 17(suppl 5):S107.
18. Obeso JA, Guridi J, Rodriguez-Oroz MC, et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345:956-963.
19. Kleiner-Fisman G, Fisman DN, Sime E, et al. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003;99:489-495.
20. Rodriguez-Oroz MC, Zamarbide I, Guridi J, et al. Double-blind evaluation of the efficacy of deep brain stimulation of the subthalamic in Parkinson's disease 4 years after surgery. J Neurol Neurosurg Psychiatry (in press).
21. Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001;56:548-551.
22. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neutoprotection. Ann Neurol 1998;44:S175-S188.
23. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:166-230.
24. Braak H, Braak E, Yilmazer D, et al. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;46:15-31.
25. Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm 2000;59: 185-212.
26. Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39(11 suppl 2):7-10.
27. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6:889-897.
28. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
29. Parkinson Study Group. Pramipexole versus levodopa in early Parkinson's disease: a randomized controlled trial. JAMA 2000; 284:1931-1938.
30. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
31. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-2066.
32. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241.
33. Kirik D, Georgievska B, Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 2004;7:105-110.
34. Lindvall O, McKay R. Brain repair by cell replacement and regeneration. Proc Natl Acad Sci USA 2003;100:7430-7431.
35. Brown RG, Dowsey PL, Brown P, et al. Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease. Ann Neurol 1999;45:473-488.
36. Jahanshahi M, Ardouin CMA, Brown RG, et al. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 2000;123:1142-1154.
37. Artieda J, Pastor MA, LaCruz F, Obeso JA. Temporal discrimination is abnormal in Parkinson's disease. Brain 1992;115: 199-210.
38. Schultz W, Apicella P, Ljungberg T, et al. Reward-related activity in the monkey striatum and substantia nigra. Prog Brain Res 1993;99:227-235.
39. Del Tredici K, Rüb U, De Vos RAI, et al. Where does Parkinson disease pathology begin in the brain? J Neuro Pathol Exp Neurol 2002;61:413-426.
40. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
41. Bjorklund A, Dunnett SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003;2:437-445.
42. Golbe LI, Mouradian MM. Alpha-synuclein in Parkinson's disease: light from two new angles. Ann Neurol 2004;55: 153-156.
43. 10 in early Parkinson disease-evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
44. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J Pharmacol Exp Ther 1999;288:421-427.
45. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998;44:S110-S114.
46. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998;44:S115-S120.